Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates Fzd2. The antibody may specifically bind Fzd2, and may promote internalization of the Fzd2 receptor by the cancer cells and/or prevent ligand binding to Fzd2. Specific antibodies, and also specific portions of the Fzd2 molecule for antibody binding are disclosed. In one embodiment the antibody specifically binds to the epitope HGAEQICVGQNHSEDGAPAL (SEQ ID NO: 1). Specific cancers (e.g. late stage hepatocellular carcinoma), intended for treatment are provided, and include cancers that exhibit overexpression of Fzd2, and/or Wnt5a.
1. A method of treating cancer in a subject that exhibits overexpression of Fzd2 or overexpression of Wnt5a comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds Fzd2 within a region corresponding to amino acids 125-163 and downmodulates Fzd2, such that the antibody or antigen binding fragment thereof is delivered to cancer cells of the subject, to thereby treat the cancer.
2. A method of inhibiting growth, migration and/or invasion of a cancer cell that exhibits overexpression of Fzd2 or overexpression of Wnt5a in a subject comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds Fzd2 within a region corresponding to amino acids 125-163 and downmodulates Fzd2, such that the antibody or antigen binding fragment thereof is delivered to the cancer cells, to thereby treat the cancer.
3. The method of claim 2 , wherein the antibody promotes internalization of Fzd2 by the cancer cells.
4. The method of claim 2 , wherein the antibody prevents ligand binding to Fzd2.
5. The method of claim 2 , wherein the antibody specifically binds to Fzd2 within a region of Fzd2 corresponding to amino acids 134-163 of Fzd2.
6. The method of claim 2 , wherein the antibody specifically binds to Fzd2 within a region of Fzd2 corresponding to amino acids 144-163 of Fzd2.
7. The method of claim 2 , wherein the antibody specifically binds to the epitope HGAEQICVGQNHSEDGAPAL (SEQ ID NO: 1).
8. The method of claim 2 , wherein the antibody is monoclonal.
9. The method of claim 2 , wherein the antibody is polyclonal.
10. The method of claim 2 , wherein the antibody is humanized.
11. The method of claim 2 , wherein the cancer is selected from the group consisting of gastrointestinal cancer, prostate cancer, ovarian cancer, breast cancer, head and neck cancer, lung cancer, non-small cell lung cancer, cancer of the nervous system, kidney cancer, retina cancer, skin cancer, liver cancer, pancreatic cancer, genital-urinary cancer and bladder cancer.
12. The method of claim 11 , wherein the cancer is liver cancer.
13. The method of claim 12 , wherein the cancer is late stage hepatocellular carcinoma.
14. The method of claim 1 , wherein the antibody promotes internalization of Fzd2 by the cancer cells.
15. The method of claim 1 , wherein the antibody prevents ligand binding to Fzd2.
16. The method of claim 1 , wherein the antibody specifically binds to Fzd2 within a region of Fzd2 corresponding to amino acids 134-163 of Fzd2.
17. The method of claim 1 , wherein the antibody specifically binds to Fzd2 within a region of Fzd2 corresponding to amino acids 144-163 of Fzd2.
18. The method of claim 1 , wherein the antibody specifically binds to the epitope HGAEQICVGQNHSEDGAPAL (SEQ ID NO: 1).
19. The method of claim 1 , wherein the antibody is monoclonal.
20. The method of claim 1 , wherein the antibody is polyclonal.
21. The method of claim 1 , wherein the antibody is humanized.
22. The method of claim 1 , wherein the cancer is selected from the group consisting of gastrointestinal cancer, prostate cancer, ovarian cancer, breast cancer, head and neck cancer, lung cancer, non-small cell lung cancer, cancer of the nervous system, kidney cancer, retina cancer, skin cancer, liver cancer, pancreatic cancer, genital-urinary cancer and bladder cancer.
23. The method of claim 22 , wherein the cancer is liver cancer.
24. The method of claim 23 , wherein the cancer is late stage hepatocellular carcinoma.